Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Acute Kidney Injury Related to Intravenous Colistin Use in Lebanese Hospitalized Patients: Incidence and Associated Factors

Author(s): Malak Khalifeh*, Abdalla El-Lakany and Lama Soubra

Volume 17, Issue 2, 2022

Published on: 28 April, 2022

Page: [152 - 157] Pages: 6

DOI: 10.2174/1574886316666210728113905

Price: $65

Abstract

Background: Colistin use has increased because of the emergence of infections caused by resistant gram-negative bacteria. Acute kidney injury (AKI) remains a treatment-limiting factor for widespread colistin clinical use. This study aimed at determining the incidence and the factors associated with the development of colistin-induced AKI.

Methods: A retrospective observational study was conducted by reviewing files of adult patients with normal kidney function between January 2015 to March 2019 at a university hospital located in Beirut city. AKI was defined based on KDIGO criteria. Independent variables associated with colistin-induced AKI were also tested.

Results: In this study, a total of 113 patients were included. AKI occurred in 53 patients (46.9%). The Charlson Comorbidity Index (CCI) was found to be significantly greater in the AKI group (2.26, P-value = 0.026). In the multivariate analysis, low serum albumen was found as an independent significant predictor for AKI (OR=.065, 95%CI: .013-.337, P-value=0.001). Moreover, the risk for AKI increased by 2 folds (OR=2.019, 95%CI: 1.094-3.728, P-value: 0.025), when two or more nephrotoxic agents were administered simultaneously with colistin. The patient’s age was also found as a significant predictor for AKI (OR=1.034, 95%CI:1-1.07), with a cut-off value of 58.5-year-old.

Conclusion: This study demonstrated that the concomitant use of two or more nephrotoxic drugs, patient’s age of 58.5 or above, and the presence of hypoalbuminemia were independent factors for the development of colistin-induced AKI. These factors should be therefore taken into consideration when prescribing colistin in clinical practice to decrease the risk of AKI.

Keywords: Colistin, acute kidney injury, nephrotoxicity, length of hospital stay, KDIGO criteria, nephrotoxic drugs.

« Previous Next »
[1]
Martis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: A narrative review for the clinician. J Infect 2014; 69(1): 1-12.
[http://dx.doi.org/10.1016/j.jinf.2014.03.001] [PMID: 24631777]
[2]
Johnson R, Ed. Comprehensive clinical nephrology (6th ed) Philadelphia, PA Lippincott Williams & Wilkins. 2010.
[3]
Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol 2015; 71(7): 801-10.
[http://dx.doi.org/10.1007/s00228-015-1865-4] [PMID: 26008213]
[4]
Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49(8): 3136-46.
[http://dx.doi.org/10.1128/AAC.49.8.3136-3146.2005] [PMID: 16048915]
[5]
Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 2006; 10(1): R27.
[http://dx.doi.org/10.1186/cc3995] [PMID: 16507149]
[6]
Lee YJ, Wi YM, Kwon YJ, Kim SR, Chang SH, Cho S. Association between colistin dose and development of nephrotoxicity. Crit Care Med 2015; 43(6): 1187-93.
[http://dx.doi.org/10.1097/CCM.0000000000000931] [PMID: 25756417]
[7]
Ghafur A, Gohel S, Devarajan V, et al. Colistin nephrotoxicity in adults: Single centre large series from India. Indian J Crit Care Med 2017; 21(6): 350-4.
[http://dx.doi.org/10.4103/ijccm.IJCCM_140_17] [PMID: 28701840]
[8]
Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5: 1.
[http://dx.doi.org/10.1186/1471-2334-5-1] [PMID: 15642116]
[9]
Min KL, Son ES, Kim JS, Kim SH, Jung SM, Chang MJ. Risk factors of colistin safety according to administration routes: Intravenous and aerosolized colistin. PLoS One 2018; 13(11): e0207588.
[http://dx.doi.org/10.1371/journal.pone.0207588] [PMID: 30462703]
[10]
Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med 2013; 35(2): 121-6.
[http://dx.doi.org/10.4103/0253-7176.116232] [PMID: 24049221]
[11]
Concept. Charlson Comorbidity Index 2019. Available from: http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?printer=Y&conceptID=1098
[12]
National Guideline Clearing House. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1-138.
[13]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[14]
Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015; 35(1): 28-33.
[http://dx.doi.org/10.1002/phar.1493] [PMID: 25266910]
[15]
Sorlí L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study. BMC Infect Dis 2013; 13: 380.
[http://dx.doi.org/10.1186/1471-2334-13-380] [PMID: 23957376]
[16]
Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014; 46(10): 678-85.
[http://dx.doi.org/10.3109/00365548.2014.926021] [PMID: 25073536]
[17]
Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141(6): 1214-22.
[http://dx.doi.org/10.1017/S095026881200194X] [PMID: 22954403]
[18]
Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014; 43(4): 349-52.
[http://dx.doi.org/10.1016/j.ijantimicag.2013.12.002] [PMID: 24439066]
[19]
Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011; 62(2): 187-90.
[http://dx.doi.org/10.1016/j.jinf.2010.11.013] [PMID: 21129401]
[20]
Özkarakaş H, Köse I, Zincircioğlu Ç, et al. Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients. Turk J Med Sci 2017; 47(4): 1165-72.
[http://dx.doi.org/10.3906/sag-1604-60] [PMID: 29156858]
[21]
Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54(10): 4503-5.
[http://dx.doi.org/10.1128/AAC.01707-09] [PMID: 20660694]
[22]
Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53(9): 879-84.
[http://dx.doi.org/10.1093/cid/cir611] [PMID: 21900484]
[23]
Ko Hj, Jeon Mh, Choo Ej, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117(3): c284-8.
[http://dx.doi.org/10.1159/000320746] [PMID: 20847571]
[24]
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis. Kidney Int 2012; 81(5): 442-8.
[http://dx.doi.org/10.1038/ki.2011.379] [PMID: 22113526]
[25]
Schiffl H, Lang SM, Fischer R. Long-term outcomes of survivors of ICU acute kidney injury requiring renal replacement therapy: A 10-year prospective cohort study. Clin Kidney J 2012; 5(4): 297-302.
[http://dx.doi.org/10.1093/ckj/sfs070] [PMID: 25874084]
[26]
Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16(11): 3365-70.
[http://dx.doi.org/10.1681/ASN.2004090740] [PMID: 16177006]
[27]
Korkeila M, Ruokonen E, Takala J. Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care. Intensive Care Med 2000; 26(12): 1824-31.
[http://dx.doi.org/10.1007/s001340000726] [PMID: 11271091]
[28]
Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: A prospective evaluation. Int J Antimicrob Agents 2005; 26(6): 504-7.
[http://dx.doi.org/10.1016/j.ijantimicag.2005.09.004] [PMID: 16280245]
[29]
Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72(6): 857-68.
[http://dx.doi.org/10.7326/0003-4819-72-6-857] [PMID: 5448745]
[30]
Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006; 12(12): 1227-30.
[http://dx.doi.org/10.1111/j.1469-0691.2006.01559.x] [PMID: 17121631]
[31]
Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35(5): 473-7.
[http://dx.doi.org/10.1016/j.ijantimicag.2009.12.002] [PMID: 20089383]
[32]
Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009; 34(5): 434-8.
[http://dx.doi.org/10.1016/j.ijantimicag.2009.06.028] [PMID: 19726164]
[33]
Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1(1): 14.
[http://dx.doi.org/10.1186/2110-5820-1-14] [PMID: 21906345]
[34]
Omrani AS, Alfahad WA, Shoukri MM, et al. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob 2015; 14: 3.
[http://dx.doi.org/10.1186/s12941-015-0062-8] [PMID: 25591721]
[35]
Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011; 31(12): 1257-64.
[http://dx.doi.org/10.1592/phco.31.12.1257] [PMID: 22122186]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy